Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.
about
Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune DiseasesObstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implicationsMutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohortPros and cons for C4d as a biomarker.Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome.Increase in complement iC3b is associated with anti-inflammatory cytokine expression during late pregnancy in miceDysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.New therapeutic targets for the antiphospholipid syndrome.Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome.Defective complement inhibitory function predisposes to renal disease.Pathophysiology of the antiphospholipid antibody syndrome.Antiphospholipid Syndrome during pregnancy: the state of the artAnti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss.The complement system at the embryo implantation site: friend or foe?Unilateral uterine ischemia/reperfusion-induced bilateral fetal loss and fetal growth restriction in a murine model require intact complement component 5.The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro.Pathogenesis of antiphospholipid syndrome: understanding the antibodies.Guidelines on the investigation and management of antiphospholipid syndrome.Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine?Antiphospholipid syndrome: an update for clinicians and scientists.Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.High-dose unfractionated heparin therapy in a pregnant patient with antiphospolipid syndrome: a case report.Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta.Antiphospholipid syndrome: interpretation of laboratory data.Positive C4d immunostaining of placental villous syncytiotrophoblasts supports host-versus-graft rejection in villitis of unknown etiology.Complement split product C4d deposition in placenta in systemic lupus erythematosus and pregnancy-induced hypertension.Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.Increased C4d and Bb immunoreactivity and decreased MBL immunoreactivity characterise first-time pathologic first-trimester miscarriage: a case-control study.Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.Abdominal pain, flank pain, blurry vision, and lower extremity weakness in a 16-year-old female.Placental C4d deposition is a feature of defective placentation: observations in cases of preeclampsia and miscarriage.Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications.Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome
P2860
Q26766486-3CCCF121-0AD3-4328-AB91-54497614875BQ26998188-C7616E4F-5489-46CD-9202-814A12672190Q28741729-FBDCCAC7-E20C-42C5-8BB7-31CD1AEC0310Q30544649-FD8EF2EC-F96F-4D3F-83C5-6F8D6EA7A0A5Q33388474-2D3443E1-DAB2-4084-9557-0F79E4BF0FD8Q33431097-7BDC87F8-EDE7-4295-A760-D192FDBC339FQ33728591-AE6A5F2E-B6B2-43AF-86EB-3E45A74194A4Q33976312-EE3F2310-C758-4E47-BA23-C335C1B882BAQ34140319-1BCF5A3E-2051-496C-B393-4775DA0C00DBQ34287356-D9E8F643-54AB-4AC9-8D5B-0BFFB21D832FQ34465747-CB56CCD0-B1D2-4ED1-A41F-437B939382A8Q35309024-B8940AE2-27AF-4F80-AF41-E1A7ACEA0151Q35756040-583587DC-68CB-4D2E-B61D-6096C9B43D6EQ35854768-AEF88695-3178-497B-BF5C-357335DEFC56Q35927443-B33CB597-AC0C-4347-A2AE-76D7AE62C609Q36205244-48A9C319-9E7A-4716-A240-95778196B881Q36975531-F31B9C01-CC3F-4ADF-A4DB-1C63F3753257Q37873720-6571B545-D3F9-45E9-9886-A52D54ABD0B0Q37982121-421F061D-0C63-4425-909C-3AAE78804460Q38193203-1C6D0B61-4E85-48AA-8552-42C49AAC016DQ38679842-8690D1FC-38A6-4E4D-8203-DBEC1519ED1BQ38876334-627C754E-BC75-48E9-B58C-688A65D06940Q39264755-DDA56DBA-1E31-45A9-BBF3-38650DC9F577Q41915133-D8D2B490-FE9B-49C5-BCCC-8A5F3EAB399BQ42939562-CD71732F-7261-4256-92B9-6A2355463456Q44237362-5C03D5A0-3C36-419D-8B11-2C1655D20510Q44719836-3A6748B4-9E02-4627-BD2F-A94ED0A4439AQ44940106-8E000707-956A-4CED-92EE-D6436D674B68Q46493708-47D37189-7CC3-4507-B597-F06AF4D99371Q47796610-3D79226D-4909-4CD9-AFE9-BEEC4F801410Q48003583-0F144F0A-96B5-4A10-82C4-CDAF6311D7EAQ48164014-079FE858-7204-45FF-9999-BC2B596CB798Q51144375-4512113C-3E16-4A04-A50C-95F01A3D8095Q53565891-70AB5A50-4BEC-44EB-8D9A-995AF4821425Q55407136-B78ACCF6-580B-4028-8113-FE0B95299657Q58776407-29627D11-03AA-4518-B0BE-845E85739C98
P2860
Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Excessive complement activatio ...... h antiphospholipid antibodies.
@ast
Excessive complement activatio ...... h antiphospholipid antibodies.
@en
type
label
Excessive complement activatio ...... h antiphospholipid antibodies.
@ast
Excessive complement activatio ...... h antiphospholipid antibodies.
@en
prefLabel
Excessive complement activatio ...... h antiphospholipid antibodies.
@ast
Excessive complement activatio ...... h antiphospholipid antibodies.
@en
P2093
P2860
P1476
Excessive complement activatio ...... h antiphospholipid antibodies.
@en
P2093
Elizabeth Hyjek
Jaime M Shamonki
Jane E Salmon
Rebecca N Baergen
P2860
P304
P356
10.1016/J.AJOG.2006.10.879
P407
P577
2007-02-01T00:00:00Z